For the quarter ending 2025-09-30, IRD has $36,122K in assets. $30,155K in debts. $30,815K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 30,815 | 32,429 | ||
| Accounts receivable | 2,916 | 3,399 | ||
| Contract assets and unbilled receivables (note 11) | 1,364 | 1,178 | ||
| Prepaids and other current assets | 815 | 1,433 | ||
| Short-term investments | 0 | 0 | ||
| Total current assets | 35,910 | 38,439 | ||
| Property and equipment, net | 212 | 226 | ||
| Total assets | 36,122 | 38,665 | ||
| Accounts payable | 2,395 | 1,465 | ||
| Warrant liabilities | 21,325 | 11,800 | ||
| Accrued expenses and other liabilities | 5,367 | 6,927 | ||
| Total current liabilities | 29,087 | 20,192 | ||
| Long-term funding agreement, related party | 1,068 | 1,000 | ||
| Total liabilities | 30,155 | 21,192 | ||
| Common stock, par value 0.0001 125,000,000 shares authorized as of september 30, 2025 and december 31, 2024 64,544,096 and 31,574,657 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 6 | 6 | ||
| Additional paid-in capital | 178,027 | 172,079 | ||
| Accumulated deficit | -172,066 | -154,612 | ||
| Total stockholders' equity | 5,967 | 17,473 | ||
| Total liabilities, series a preferred stock and stockholders' equity | 36,122 | 38,665 | ||
Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (IRD)